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Introduction: Pulmonary carcinoids associated with ectopic adrenocorticotropic hormone secretion have a good
prognosis if histological examination shows typical pulmonary carcinoid and low proliferation, whereas a poor
outcome is linked to atypical pulmonary carcinoid and high proliferation. Here we describe the diagnostic
challenges to find the tumor in Cushing’s syndrome secondary to ectopic adrenocorticotropic hormone secretion
in two cases with an atypical and a typical pulmonary carcinoid, respectively.
Case presentation: A 63-year-old Caucasian woman presented with aggressive clinical features related to
Cushing’s syndrome, having very high levels of urinary cortisol and circulating adrenocorticotropic hormone and
cortisol. Magnetic resonance imaging showed no pituitary tumor, and bilateral inferior petrosal sinus sampling
revealed no central peripheral ratio of adrenocorticotropic hormone. Computed tomography and 111Indium-
pentetreoide somatostatin receptor scintigraphy could not visualize any ectopic tumor. The patient was referred for
an 11C-5-hydroxytryptophan positron emission tomography, and a small 8mm nodule in her left lung was found.
The tumor was removed via a lateral thoracic incision and wedge excision. The histological examination showed an
atypical carcinoid with Ki-67 index of 9 to 10%, and an additional lobectomy was performed.
The second patient, a 22-year-old Caucasian man, also presented with aggressive Cushing’s syndrome, with very
high urinary cortisol levels and increased circulating cortisol as well as adrenocorticotropic hormone levels. A
magnetic resonance imaging scan of the pituitary showed no tumor, whereas a 12×9×14mm tumor was detected
in the right lung on the primary computed tomography scan and no further investigation was performed. The
tumor was removed via a lateral thoracic incision and wedge excision. A typical carcinoid with Ki-67 index of 1 to
2% was found and no further surgery was performed.
After surgical removal, the biochemical disturbances resolved and significant clinical improvement were achieved in
both patients after 24 months of follow up.
Conclusions: Diagnostic evaluation time is limited due to the aggressive course in ectopic adrenocorticotropic
hormone-dependent Cushing’s syndrome. We suggest that 11C-5-hydroxytryptophan positron emission tomography
could be considered early as a secondary diagnostic tool when primary computed tomography and/or magnetic
resonance imaging scans fail to show any tumor.
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Neuroendocrine tumors found in the thymus, thyroid,
lungs, adrenals, gastrointestinal tracts and pancreas have
been associated with ectopic adrenocorticotropic hor-
mone (ACTH)- dependent Cushing’s syndrome (CS), with
small cell lung carcinoma and pulmonary carcinoids ac-
counting for the most cases [1-4]. In cases with a small
cell carcinoma in the lung the radiological visualization of
a tumor mass is in general obvious, whereas in ACTH-
producing pulmonary carcinoids localization of the tumor
could be unsuccessful using modalities like computed
tomography (CT) and magnetic resonance imaging (MRI)
of the patient's chest and abdomen [5]. Other techniques
used to detect ectopic ACTH-secreting tumors with vari-
ous results are somatostatin receptor scintigraphy (SRS)
using 111indium-pentetreotide (111In-pentetreotide-SRS)
[6] or technetium-99m-labeled octreotide acetate (Tc-
99m-SRS) [7]. Pacak et al. found that fluorodeoxyglucose
positron emission tomography (FDG-PET) did not detect
ectopic ACTH-secreting tumors that were occult on CT
and MRI [8], whereas 11C-5-hydroxytryptophan-PET
(11C-5-HTP-PET) has been shown to visualize more and
smaller lesions including pulmonary carcinoids compared
with CT and SRS [5,9].
Here, we describe two cases with ACTH-producing
pulmonary carcinoid tumor diagnosed preoperatively
with 11C-5-HTP-PET and thoracic CT scan, respectively.
The localization techniques and prognostic factors of
pulmonary carcinoids are further discussed.
Case presentation
Case 1
A 63-year-old Caucasian woman was referred from a
county hospital with an initial diagnosis of CS. She
presented with generalized fatigue, muscle weakness, in-
somnia, flushing, hypertension, stress symptoms and
psychiatric symptoms (deteriorated concentration, mem-
ory disabilities and hypomania). A physical examination
revealed the typical clinical features of a severe CS:
hypertension, changed body constitution, moon face,
supraclavicular fat, buffalo hump, hirsutism on her chin,
proximal myopathy, but also a weight loss (5kg over a
few months). Her previous medical history included
breast cancer (right side) 16 years earlier, cured with sur-
gery and radiation. She had also had a superficial malig-
nant melanoma on her right arm in year 2000 with no
recurrence. Results of a biochemical test confirmed the
diagnosis with 24-hour urine free cortisol (1300nmol/
24-hour, reference <183). She had no diurnal rhythm
and serum cortisol was around 600 to 1000nmol/L and
plasma ACTH levels were between 30 and 45ng/L dur-
ing the whole 24-hour sampling period. She did not sup-
press her cortisol and ACTH levels at all on either 1mg
or 8mg dexamethasone suppression tests. An MRI scanof her sella turcica found no pituitary tumor. Bilateral
inferior petrosal sinus sampling with corticotrophin-
releasing hormone (CRH) testing revealed no central to
peripheral ratio of ACTH, nor did ACTH increase dur-
ing the CRH test. Fasting CRH was normal 3.5pmol/L
(reference <5) and catecholamines and hydroxyindolea-
cetic acid in urine showed normal values. Chromogranin
A was slightly elevated to 8.2nmol/L (reference <6). The
patient did not have any proton-pump inhibitor. At this
stage the clinical and imaging findings raised suspicion
of an ectopic ACTH-producing tumor. A neck, thoracic
and abdominal CT scan was done, showing only a slight
enlargement of her left adrenal gland with attenuation of
25 Hounsfield units. Further, 111In-pentetreotide-SRS
was performed in the whole body planar after an injec-
tion of 166 MBq 111Indium-labeled octreotide. The scan
demonstrated no uptake typical for an ectopic ACTH
source.
Before we had the results from the sinus petrosus sam-
pling, treatment with cabergoline was added, but it was
quickly withdrawn due to side effects of dizziness, nau-
sea, and uncontrollable shaking. The reason to start with
cabergoline and not with ketoconazole was moderately
elevated liver enzymes. However, despite the deterior-
ation in liver enzymes the patient was commenced on
ketoconazole 200mg twice daily. She also received
metapyrone (metyrapone) in increasing doses up to 2.5g,
which could not be increased more due to side effects
with increased flushing and anxiety attacks. Regardless
of the increase in dose of metapyrone (metyrapone) in
addition to ketoconazole no clinical improvement was
seen, and due to further increase in the deterioration in
liver enzymes ketoconazole was discontinued. However,
her cortisol and ACTH levels were stable and did not
further increase during the investigational period. Due
to the deterioration of her health condition a bilateral
adrenalectomy was planned. Investigations with 11C-5
HTP-PET are centralized to one place in Sweden and fi-
nally we contacted the PET center in Uppsala, Sweden,
and an 11C-5-HTP-PET was performed showing an
8mm mass in the left lung lower lobe with focal uptake
(Figure 1). In retrospect, the same shadow was present
on thoracic CT, previously assessed as a vessel. A thor-
acic surgeon was contacted to perform a wedge excision
of the tumor via a lateral thoracic incision. Histology of
the removed tissue showed an atypical carcinoid tumor
with trabecular and focally insular pattern; a few areas
were showing a marked degree of nuclear pleomorphism
and hyperchromasia that is associated with the presence
of mitotic figures (up to six per 10 high power fields,
HPF). Immunohistochemistry stains were positive for
neurone-specific enolase, protein gene product 9.5,
chromogranin A, ACTH and synaptophysin. The hilar
lymph nodes were benign. Three mitoses/10HPF and
Figure 1 Investigation with 11C-5-hydroxytryptophan positron
emission tomography shows an 8mm tumor in the left lower
pulmonary lobe in a 63-year-old woman with aggressive
ectopic adrenocorticotropic hormone-dependent Cushing’s
syndrome. Tumor indicated by an arrow.
Figure 2 Investigation with computed tomography shows a
12×9×14mm tumor in the right lower pulmonary lobe in a 22-
year-old man with aggressive adrenocorticotropic hormone-
dependent Cushing’s syndrome. Tumor indicated by an arrow.
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The tumor was radically extirpated, unfortunately with a
narrow margin.
After the surgery ACTH was below the detection li-
mit (<5ng/L) with low morning cortisol levels below
100nmol/L, and replacement therapy with hydrocorti-
sone was initiated.
Due to the finding of an atypical carcinoid and the
narrow radical surgery an additional lobectomy was
performed. The histology of the whole lobe showed no
signs of recurrent tumor tissue and dissected regional
lymph nodes were benign. A new 11C-5-HTP-PET was
performed 6 and 24 months after the second operation
without any sign of new endocrine tumors. A dual-
energy X-ray absorptiometry (DXA) scan showed osteo-
porosis with T-scores of −3.0 both in L2 to L4 lumbar
spine and in total hip and she was prescribed annualzoledronic acid infusions. At 24 months follow up, she
still has low morning cortisol levels below 100nmol/L
and plasma ACTH <5ng/L before hydrocortisone intake
in the morning (total daily dose of 25mg).
Case 2
A 22-year-old Caucasian man presented with clinical
features of a severe CS including centripetal fatness,
moon face, severe edema, excessive purple striae on his
trunk, and frequent nocturia. During the last years the
patient had gained 30kg in weight despite diet and exer-
cise plans. Despite a loss of 10kg in weight during the
past months his centripetal fatness increased and he was
so swollen that his eyes hardly could be seen. The serum
cortisol concentration was 670nmol/L at 8:00 a.m., and
703nmol/L at 7.30 p.m. Plasma ACTH was 140ng/L at
8.00 a.m. (reference <46) and 140ng/L at 7.30 p.m. Sam-
pling of 24-hour urinary free cortisol showed increased
values, >3000nmol/24 hour (reference <183). He did not
suppress his cortisol or ACTH levels at all on 1mg dexa-
methasone suppression testing. His chromogranin A
levels and blood sugar levels were normal, whereas a
very low serum testosterone of 2.6nmol/L (reference 7.6
to 31) was recorded. An MRI scan of his sella turcica
did not visualize any pituitary tumor, whereas a pulmon-
ary chest radiograph and subsequent CT scan revealed a
12×9×14mm diameter mass in the right lower pulmon-
ary lobe (Figure 2). Because of the severe symptoms no
further investigation was performed besides bronchos-
copy and he was referred for subacute surgery. The
tumor in the right lung was removed via a lateral thor-
acic incision by wedge excision. Histology confirmed a
typical carcinoid with <1 mitosis/10HPF, and no necrosis
was found. Ki-67 immunostaining was generally positive
in 1 to 2% of the tumor cells and focally up to 5%. The
tumor cells stained positive for ACTH, chromogranin A,
and synaptophysin. Dexamethasone (1mg) suppression
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46nmol/L, although ACTH suppressed only to 25ng/L.
However, 24-hour urinary free cortisol was very low, re-
vealing a value of 28nmol/24-hour. No further surgery
was performed. Initially he achieved replacement therapy
with hydrocortisone, but he stopped substitution after a
few months. A DXA scan showed normal bone mineral
density. At current follow up after 24 months he is in
clinical remission and his diurnal urinary cortisol is still
in the lower normal range.
Discussion
Even if lung carcinoids have a better prognosis than
other ACTH-secreting neuroendocrine tumors like small
cell carcinomas, thymic carcinoids, medullary thyroid
carcinomas and gastrinomas, they are a malignant dis-
ease with potential for metastases and increased mortal-
ity [1,10]. The present cases illustrate the dilemma
between the need for morphological diagnosis of the ec-
topic ACTH source and control of the life-threatening
hypercortisolism. A great help in our first patient was bi-
lateral inferior petrosal sinus sampling with CRH stimu-
lation for the differential diagnosis between pituitary and
ectopic sources of ACTH [11], even if false positive
cases have been reported [12]. There is no single diag-
nostic imaging technique for pulmonary carcinoid tu-
mors. CT remains the gold standard for demonstrating
abnormal mass in the chest [13]. In our second patient,
a normal MRI scanning of the sellar region and a lung
tumor identified with CT indicated ectopic origin of the
ACTH-producing tumor, whereas in our first patient
further investigation was needed.
The usefulness of Tc-99m-SRS has been described in
selected cases with success [7] and may have advantages
over 111In-pentetreotide-SRS used in our patient, with
lower radiation dose and lower costs [6]. However, the
tumor was not detected in our first patient and this
could be due to possible lack of somatostatin receptors
in the tumor or the size being only 8mm, which is near
the resolution limit of 6mm for SRS methods [6]. FDG-
PET was accessible, but this investigation did not
visualize ectopic ACTH-secreting tumors that were oc-
cult [8]. Therefore we decided to refer the patient for
11C-5-HTP-PET instead. Neuroendocrine tumors have a
capacity for uptake and decarboxylation of amine pre-
cursors like 5-HPT, which can be used as a tracer for
PET imaging [5]. Compared with CT and SRS, 11C-5-
HTP-PET has been shown to visualize more and smaller
lesions down to 4 to 5mm [5,9]. Also, because of the
biochemical pathway of 5-HPT, the nature of a lesion
may be demonstrated (tumor, inflammation) [5,9] and,
contrary to SRS, inflammatory lesions do not generally
accumulate the tracer. In our first patient 11C-5-HTP-
PET was essential for the diagnosis. The patient wasonly days from bilateral adrenalectomy, which is an ef-
fective treatment [14], but it would have had left her
with a remaining atypical carcinoid in the lung with a
poor prognosis [15]. We suggest that all modalities have
to be used in searching for an occult ACTH-producing
tumor, and in our first patient 11C-5-HTP-PET in an
earlier stage had been preferable. Moreover, we did not
perform any SRS or 11C-5-HTP-PET before primary sur-
gery in the second patient as suggested by some authors
[5], which has given us more uncertainty postoperatively
regarding remaining tumor.
In our department the routine procedure for pulmon-
ary carcinoids is surgery with wedge excision aiming to
save lung parenchyma. Young age, central tumor, and
no nodal enlargement are highly suggestive of typical
carcinoid and recent guidelines advocate no further
diagnostic or staging tests beyond chest CT and bron-
choscopy before resection using parenchyma-sparing
techniques [16]. However, some authors suggest that
surgical removal of the lung carcinoid tumor should
aim at “anatomic resection” rather than “parenchyma
saving” surgery. This can be true in older patients and
women who more often have small nodules with diame-
ters of less than 5mm that are histologically similar to
carcinoids (tumorlets) [16]. Search for involved medias-
tinal lymph nodes should be rigorous, and a low thresh-
old for clearing lymph nodes should be adopted also in
typical carcinoids [17]. Failure to remove all involved
lymph nodes could lead to persistence or recurrence of
the syndrome, and diminishes the chances of long-term
survival [15]. Serum ACTH could be used as a tumor
marker to predict early recurrence. Besides ACTH,
these tumors were shown to secrete a number of bio-
logically active hormones and precursors that could
cause Cushing’s syndrome. CRH, corticotrophin-like
intermediate lobe peptide, ACTH precursors, and pro-
opiomelanocortin were among the described factors [18].
Taken together, if the tumor can be visualized with SRS
or 11C-5-HTP-PET preoperatively in addition to labora-
tory specimens the post-surgery follow up is facilitated [5].
Conclusions
Diagnostic evaluation time is limited due to the aggres-
sive course in ectopic ACTH-dependent CS. We suggest
that a referral to a specialized center for investigation
with 11C-5-HTP-PET in selected cases is preferable
when a CT and MRI examination fail to detect any ec-
topic ACTH-producing tumor.
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